miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodeling

FASEB Journal

Volumn 27, Issue 10, 2013, Pages 4254-4265

  Li, Shu Hong ^a,b,c   Guo, Jian ^a,b,c   Wu, Jun ^a,b,c   Sun, Zhuo ^a,b,c   Han, Mihan ^a,b,c   Shan, Sze Wan ^d   Deng, Zhaoqun ^d   Yang, Burton B ^d   Weisel, Richard D ^a,b,c   Li, Ren Ke ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

MMP; Myocardial infarction; TIMP1; TIMP2

Indexed keywords

ANTAGOMIR; GELATINASE B; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 17; MICRORNA 20A; MICRORNA 20B; MICRORNA 93; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; MIRN17 MICRORNA, MOUSE; OLIGONUCLEOTIDE; TIMP1 PROTEIN, MOUSE;

3' UNTRANSLATED REGION; ANIMAL TISSUE; ARTICLE; CARDIAC MATRIX REMODELING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE FUNCTION; IN SITU HYBRIDIZATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; UPREGULATION; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; HEART VENTRICLE REMODELING; HEK293 CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIUM; OLIGONUCLEOTIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VENTRICULAR REMODELING;

EID: 84885152873     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-231688     Document Type: Article

References (28)

1. Felkin, L. E., Birks, E. J., George, R., Wong, S., Yacoub, M. H., and Barton, P. J. (2006) A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J. Heart Lung Transplant. 25, 1413-1419
2. Vanhoutte, D., Schellings, M., Pinto, Y., and Heymans, S. (2006) Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 69, 604-613
3. Inomata, M., Tagawa, H., Guo, Y. M., Kameoka, Y., and Sawada, K. (2009) MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113, 396-402
4. Doebele, C., Bonauer, A., Fischer, A., Scholz, A., Urbich, C., Hofmann, W. K., Zeiher, A. M., and Dimmeler, S. (2010) Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 115, 4944-4950
5. Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., Jaenisch, R., Sharp, P. A., and Jacks, T. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886
6. Shan, S. W., Lee, D. Y., Deng, Z., Shatseva, T., Du, W. W., Zhang, Y., Xuan, J. W., Yee, S. P., Siragam, V., and Yang, B. B. (2009) MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat. Cell Biol. 11, 1031-1038
7. Fazel, S., Chen, L., Weisel, R. D., Angoulvant, D., Fazel, A., Cheung, P., Lam, J., Fedak, P. W., Yau, T. M., and Li, R. K. (2005) Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J. Thorac. Cardiovasc. Surg. 130, 1310
8. Fedak, P. W., De Sa, M. P., Verma, S., Nili, N., Butany, J., Strauss, B. H., Weisel, R. D., and David, T. E. (2003) Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J. Thorac. Cardiovasc. Surg. 126, 797-806
9. Li, Y. Y., Feldman, A. M., Sun, Y., and McTiernan, C. F. (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98, 1728-1734
10. Van Rooij, E., and Olson, E. N. (2007) microRNAs put their signatures on the heart. Physiol. Genomics 31, 365-366
11. Van Rooij, E., Sutherland, L. B., Thatcher, J. E., Di Maio, J. M., Marshall, W. S., Hill, J. A., and Olson, E. N. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105, 13027-13032
12. Duisters, R. F., Tijsen, A. J., Schroen, B., Leenders, J. J., Van der Madem, I., Herias, V., Van Leeuwen, R. E., Schellings, M. W., Barenbrug, P., Maessen, J. G., Heymans, S., Pinto, Y. M., and Creemers, E. E. (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170-178
13. Bonauer, A., Carmona, G., Iwasaki, M., Mione, M., Fischer, A., Burchfield, J., Fox, H., Doebele, C., Ohtani, K., Chavakis, E., Potente, M., Tjwa, M., Urbich, C., Zeiher, A. M., and Dimmeler, S. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710-1713
14. Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Liebetrau, C., Weber, M., Hamm, C. W., Roxe, T., Muller-Ardogan, M., Bonauer, A., Zeiher, A. M., and Dimmeler, S. (2010) Circulating microRNAs in patients with coronary artery disease. Circ. Res. 107, 677-684
15. Tay, Y., Zhang, J., Thomson, A. M., Lim, B., and Rigoutsos, I. (2008) MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455, 1124-1128
16. Guo, H., Ingolia, N. T., Weissman, J. S., and Bartel, D. P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840
17. Creemers, E. E., Davis, J. N., Parkhurst, A. M., Leenders, P., Hapke, E., Hauet, A. M., Escobar, P. G., Cleutjens, J. P., Smits, J. F., Daemen, M. J., Zile, M. R., and Spinale, F. G. (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 284, H364-H371
18. Ikonomidis, J. S., Hendrick, J. W., Parkhurst, A. M., Herron, A. R., Dowdy, K. B., Stroud, R. E., Hapke, E., Zile, M. R., and Spinale, F. G. (2005) Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am. J. Physiol. Heart Circ. Physiol. 288, H149-H158
19. Kandalam, V., Basu, R., Abraham, T., Wang, X., Jaworski, D. M., Oudit, G. Y., and Kassiri, Z. (2010) TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ. Res. 106, 796-808
20. Bolli, R., Chugh, A. R., D'Amario, D., Loughran, J. H., Ikram, S., Beache, G. M., Wagner, S. G., Leri, A., Hosoda, T., Sanada, F., Elmore, J. B., Goichberg, P., Cappetta, D., Solankhi, N. K., Fahsah, I., Rokosh, D. G., Slaughter, M. S., Kajstura, J., and Anversa, P. (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847-1857
21. Hare, J. M., Fishman, J. E., Gerstenblith, G., Di Fede Velazquez, D. L., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V., Brinker, J. A., Breton, E., Davis-Sproul, J., Schulman, I. H., Byrnes, J., Mendizabal, A. M., Lowery, M. H., Rouy, D., Altman, P., Wong Po Foo, C., Ruiz, P., Amador, A., Da Silva, J., McNiece, I. K., and Heldman, A. W. (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308, 2369-2379
22. Assmus, B., Walter, D. H., Seeger, F. H., Leistner, D. M., Ziegler, I., Lutz, A., Khaled, W., Klotsche, J., Tonn, T., Dimmeler, S., and Zeiher, A. M. (2013) Effect of shock wavefacilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 309, 1622-1631
23. Makkar, R. R., Smith, R. R., Cheng, K., Malliaras, K., Berman, D., Czer, L. S. C, Marban, L., Mendizabal, A., Johnston, P. V., Russell, S. D., Schuleri, K. H., Lardo, A. C, Gerstenblith, G., and Marban, E. (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379, 895-904
24. Jugdutt, B. I. (2009) Limiting fibrosis after myocardial infarction. N. Engl. J. Med. 360, 1567-1569
25. Webb, C. S., Bonnema, D. D., Ahmed, S. H., Leonardi, A. H., Clark, L. L., Stroud, R. E., Corn, W. C, Finklea, L., Zile, M. R., and Spinale, F. G. (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients following myocardial infarction: relation to left ventricular remodeling. Circulation 114, 1020-1027
26. Fazel, S., Cimini, M., Chen, L., Li, S., Fedak, P., Verma, S., Weisel, R. D., Keating, A., and Li, R. K. (2006) Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116, 1865-1877
27. Tian, H., Cimini, M., Fedak, P. W., Altamentova, S., Huang, M. L., Weisel, R. D., and Li, R. K. (2007) TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 43, 733-743
28. Angoulvant, D., Fazel, S., Weisel, R. D., Lai, T. Y., Chen, L., Rafati, S., Seneviratne, C. K., Degousee, N., and Li, R. K. (2009) Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J. Thorac. Cardiovasc. Surg. 137, 471-480